CA-PERSONALIS,-INC.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy , a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
Poster Number |
Title & Presenter |
Dates |
||
40
|
Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
|
NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
Title |
Title & Presenter |
Dates |
||
Sponsored Symposia |
NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
|
NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release
One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select
Bentley Systems Announces Winners of the 2025 Going Digital Awards17.10.2025 01:00:00 CEST | Press release
Company also recognizes key projects with Founders’ Honors, the Bentley-Envision winner for infrastructure sustainability, and the 2025 Bentley Educator of the Year (Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infr
Kinaxis Inc. to Host Third Quarter 2025 Financial Results Conference Call on November 6, 202516.10.2025 23:00:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its third quarter ended September 30, 2025. The call will be hosted on Thursday, November 6 at 8:30 a.m. Eastern Time by Bob Courteau, interim chief executive officer and chair, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the third quarter after the close of markets on Wednesday, November 5, 2025. CONFERENCE CALL DETAILSDATE: Thursday, November 6, 2025 TIME: 8:30 a.m. Eastern Time CALL REGISTRATION:https://registrations.events/direct/Q4I91416498WEBCAST:https://events.q4inc.com/attendee/875765587 (available for three months) Advance call registration Participants must register in advance for the live call. After registering, instructions on how to join the call will automatically be emailed, including dial-in informat
HCLTech and Zscaler Expand Partnership for AI-Powered Security and Network Transformation16.10.2025 20:13:00 CEST | Press release
HCLTech, a leading global technology company, and Zscaler™, a leader in cloud security, announced the expansion of their strategic partnership to provide AI-powered network transformation and enhanced zero-trust security services to enterprises worldwide. Under the new partnership scope, Zscaler's Zero Trust Exchange™ platform has been integrated with HCLTech's Cybersecurity Fusion Center (CSFC) platform. HCLTech’s AI capabilities, including SecOps and Responsible AI guardrails within HCLTech AI Force and AI Foundry are key to this partnership. This collaboration aims to enhance enterprise resilience and achieve business outcomes with a cloud-first, scalable security solution. HCLTech's Universal Managed Detection and Response (UMDR) services now integrate with Zscaler Internet Access™ (ZIA™), Zscaler Private Access™ (ZPA™) and other Zscaler components, providing context-rich threat detection, advanced analytics and faster response powered by AI and automation. Other key highlights of
Beyon Cyber and Haven Sign MoU to Launch Advanced AI-Powered SOC Capabilities in the UK and Worldwide16.10.2025 19:58:00 CEST | Press release
Beyon Cyber, part of the Beyon Group and the fastest growing cyber security company in the Middle East, has signed a Memorandum of Understanding (MoU) with Haven Cyber Technologies, a global cyber security services provider and a Microsoft Solutions Partner, through its UK-based subsidiary ITC Secure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016047852/en/ Beyon Cyber and Haven Sign MoU Under the MoU, Beyon Cyber and Haven will form a strategic partnership to revolutionize cyber security operations through the launch of advanced AI-driven Security Operations Centers (AI SOCs) in the United Kingdom and worldwide. As part of this collaboration, Haven will integrate Beyon Cyber’s cutting-edge AI SOC platform, Orryx AI, into its operations; harnessing the power of smart automation and agentic AI workflows to enhance threat detection, investigation, hunting, intelligence, and response. This partnership will enable both or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom